GGrantIndex
← Leaderboards

Adriana Hung

Vanderbilt University

$417,520
Attributed
$417,520
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $225.6K · FY200725
$250K$187.5K$125K$62.5K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$417,520 · 1
VA$0 · 3

By mechanism

R21$417,520 · 1
I01$0 · 3

Top collaborators

No co-investigators on record.

Most similar at Vanderbilt University

Same institution · by research overlap

Others in their field

Top investigators on “Prevent

Research focus

PreventRisk FactorsPharmaceutical PreparationsAffectEnd Stage Renal FailureChronic Kidney FailureHypertensionCaringPrevalencePrematureCessation Of LifeMissionCardiovascular DiseasesDiabetes MellitusVeteransLinkProgramsGenetic VariantGeneticVariantKidney DiseasesDisease ProgressionGenome Wide Association StudyGlomerular Filtration Rate

Grant awards (16)

Genetic of Kidney Disease and Hypertension in MVP II$0
I01 · FY2025 · VA · contact PI
Genetics of CKD and Hypertension-Risk Prediction and Drug Response in the MVP$0
I01 · FY2024 · VA · contact PI
Genetics of CKD and Hypertension-Risk Prediction and Drug Response in the MVP$0
I01 · FY2023 · VA · contact PI
Genetics of CKD and Hypertension-Risk Prediction and Drug Response in the MVP$0
I01 · FY2022 · VA · contact PI
Genetics of CKD and Hypertension-Risk Prediction and Drug Response in the MVP$0
I01 · FY2021 · VA · contact PI
Genetics of CKD and Hypertension-Risk Prediction and Drug Response in the MVP$0
I01 · FY2020 · VA · contact PI
Pharmacogenomics of risk factors and therapies outcomes for kidney disease$0
I01 · FY2020 · VA · contact PI
Pharmacogenomics of risk factors and therapies outcomes for kidney disease$0
I01 · FY2019 · VA · contact PI
Pharmacogenomics of risk factors and therapies outcomes for kidney disease$0
I01 · FY2018 · VA · contact PI
Dysmetabolism of Chronic Kidney Disease and Vascular Health$0
I01 · FY2018 · VA · contact PI
Dysmetabolism of Chronic Kidney Disease and Vascular Health$0
I01 · FY2017 · VA · contact PI
Pharmacogenomics of risk factors and therapies outcomes for kidney disease$0
I01 · FY2017 · VA · contact PI
Dysmetabolism of Chronic Kidney Disease and Vascular Health$0
I01 · FY2016 · VA · contact PI
Dysmetabolism of Chronic Kidney Disease and Vascular Health$0
I01 · FY2015 · VA · contact PI
Inflammation, proteolysis and IL-1beta receptor inhibition in CHD patients$225,645
R21 · FY2008 · DK · contact PI
Inflammation, proteolysis and IL-1beta receptor inhibition in CHD patients$191,875
R21 · FY2007 · DK · contact PI